Arbutus Biopharma Corporation ABUS Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $23.71M+31.6% | $18.01M-19.6% | $22.41M-40.1% | $37.41M+0.9% | $37.08M+2.1% | ||
| $71.52M-2.6% | $73.46M+3.0% | $71.29M+17.5% | $60.68M-19.8% | $75.63M-12.4% | ||
| $178.74M— | $0-100% | $905K-11.7% | $1.03M-13.3% | $1.18M-50.9% | ||
| $277.01M+193% | $94.46M-3.1% | $97.44M-5.5% | $103.12M-11.7% | $116.81M-8.3% | ||
| $22K-31.3% | $32K-76.6% | $137K-7.4% | $148K-11.9% | $168K-94.9% | ||
| $277.16M+193% | $94.62M-3.2% | $97.71M-5.4% | $103.27M-11.7% | $117.01M-11.2% | ||
| $1.46M+24.6% | $1.17M+16.0% | $1.01M-23.5% | $1.32M-41.0% | $2.24M-3.3% | ||
| $5.11M-15.0% | $6.01M+15.9% | $5.18M+3.2% | $5.02M-74.2% | $19.43M+24.4% | ||
| —— | —— | —— | —— | —— | ||
| $16.99M-5.8% | $18.04M-11.2% | $20.31M+0.1% | $20.29M-46.4% | $37.85M+10.2% | ||
| $1.44B+1.6% | $1.42B+0.2% | $1.42B+0.1% | $1.42B+0.1% | $1.42B+0.4% | ||
| -$1.21B+12.3% | -$1.38B-0.3% | -$1.38B-0.6% | -$1.37B+0.2% | -$1.37B-1.8% | ||
| $260.18M+240% | $76.58M-1.1% | $77.4M-6.7% | $82.98M+4.8% | $79.16M-18.7% | ||
| $277.16M+193% | $94.62M-3.2% | $97.71M-5.4% | $103.27M-11.7% | $117.01M-11.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Arbutus Biopharma Corporation's total assets?
- Arbutus Biopharma Corporation (ABUS) holds $277.2M in total assets, up 136.9% year over year.
- How much debt does Arbutus Biopharma Corporation have?
- Arbutus Biopharma Corporation carries $631.0K in total debt against $260.2M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Arbutus Biopharma Corporation have?
- Arbutus Biopharma Corporation holds $23.7M in cash and equivalents.
- Can Arbutus Biopharma Corporation cover its short-term obligations?
- Its current ratio is 54.26 — current assets exceed current liabilities.
- Where does Arbutus Biopharma Corporation's balance sheet data come from?
- Every line is extracted from Arbutus Biopharma Corporation's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
